Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Inclusion Criteria: * Male or female study subjects≥ 18 years of age * Confirmed diagnosis of multi-focal bronchiectasis in two or more lung segments by HRCT of the chest * History of chronic infection with P. aeruginosa * Confirmation of infection with P. aeruginosa at screening * SaO2 ≥ 90% at Screening while breathing room air * Ability to comply with study medication use, study visits, and study procedures as judged by the investigator * Ability to produce at least 0.5 grams sputum or be willing to undergo an induction to produce sputum for clinical evaluation Key Exclusion Criteria: * Forced Expiratory Volume in 1 second (FEV1) \< 50% of predicted at Screening * Patients with hemoptysis of ≥60 mL within 4 weeks prior to screening * Bronchiectasis due to cystic fibrosis (CF), bronchopulmonary Aspergillus, aspiration of foreign body, or secondary to lung compression from tumors * History of non-tuberculous mycobacterial and/or Aspergillus infection requiring treatment or treated within 2 years prior to screening * Pulmonary tuberculosis requiring treatment or treated within two years prior to screening * History of Lung transplantation * Use of any inhalation or systemic antibiotics (IV antibiotics, or oral antibiotics) within 4 weeks prior to Study Day 1 * Evidence of biliary cirrhosis with portal hypertension * Smoking tobacco or any substance within 6 months prior to screening, and throughout the study * History of alcohol, medication, or illicit drug abuse within th…